600535.SHG · Tasly Pharmaceutical Group Co., Ltd

-

Please sign in to comment on 600535.SHG

1 Comment

Admin

4 years ago

Tasly Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.

From a valuation standpoint, the stock is 87.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.

Tasly Pharmaceutical Group Co., Ltd's total revenue sank by 40.8% to $3B since the same quarter in the previous year.

Its net income has increased by 77.3% to $414M since the same quarter in the previous year.

Finally, its free cash flow fell by 213.5% to $-267M since the same quarter in the previous year.

Based on the above factors, Tasly Pharmaceutical Group Co., Ltd gets an overall score of 2/5.

ISIN	CNE000001C81
Exchange	SHG
CurrencyCode	CNY
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Beta	0.44
Target Price	17.2
Market Cap	23B
PE Ratio	23.31
Dividend Yield	None

ABOUT

Tasly Pharmaceutical Group Co., Ltd

Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.

600535.SHG · Tasly Pharmaceutical Group Co., Ltd

-

Tasly Pharmaceutical Group Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Tasly Pharmaceutical Group Co., Ltd using a moving average strategy